Biography & Net Worth: Testing for Alzheimer’s disease provides the very necessary answer for patients and their families

credit: AIXabay / CC0 Public Domain

Currently, more than 500,000 Canadians suffer from Alzheimer’s disease or related dementia, and with the population aging rapidly, that number is projected to double by 2031. Now, new tests could help patients find the answer they’ve been looking for. His family planning in the face of a diagnosis of Alzheimer’s disease.

Dr. Paul’s Hospital clinical chemist and clinical associate professor at the University of British Columbia in Vancouver, Canada. “It’s an urgent and rapidly growing health problem,” says Maridemarco. His team developed an important element of the Alzheimer’s disease test and worked with individuals who have experienced dementia. Health providers and other partners will implement a comprehensive clinical trial strategy through the Impact-AD project, partly funded by Brain Canada. “The Alzheimer’s disease biomarker test, now available to all Canadians, helps physicians to accurately diagnose the disease even with only mild symptoms. Through the Impact-AD project we aimed to understand how this was done. Testing affects personal and medical decisions, medical bills..”

According to DeMarco, Impact-AD aims to inform positive changes to Canada’s health care system to improve care and support for individuals with Alzheimer’s disease and their families.

Who can give the exam?

Testing for biomarkers of Alzheimer’s disease under this program can only be ordered by physicians specializing in dementia care. Your doctor may recommend testing for individuals who are experiencing mild to moderate symptoms associated with Alzheimer’s disease. Measuring changes in these biomarkers cerebrospinal fluid, the fluid that surrounds the brain and spinal cord, helps doctors identify whether symptoms are due to Alzheimer’s disease and whether symptoms may worsen over time.

DeMarco and his colleagues are working to remove barriers to further use in the Canadian medical system, including feedback from patients, their families, and their physicians.

How can this test help people who are experiencing memory loss or poor brain health?

Early and accurate diagnosis of Alzheimer’s disease health care and community services can lead to more effective treatment and improved quality of life. Current approaches to diagnosis rely on imaging and observation of signs and symptoms of the disease. Adding measurements of proteins in cerebrospinal fluid (biomarkers) predicts people with mild symptoms who may progress to dementia.

The study appeared last year Alzheimer’s disease and dementia: diagnosis, evaluation, disease monitoring,

Early accumulation of tau in the brain predicts memory loss in Alzheimer’s disease

for more information:
Mari L. DeMarco et al, Automated clinical mass spectrometry for the identification and quantification of mutant and wild-type amyloid-β1-40 and 1-42 peptides in CSF, Alzheimer’s disease and dementia: diagnosis, evaluation, disease monitoring (2020). DOI: 10.1002/dad2.12036

Provided by Brain Canada Foundation

Citation: Trial for Alzheimer’s disease was retrieved from on December 15, 2021 for patients and their families (December 15, 2021). ) provides much needed answers

This document is subject to copyright. No part may be reproduced without written permission, except in reasonable transactions for personal investigation or research purposes. The content is provided for informational purposes only.

Testing for Alzheimer’s disease provides much-needed answers for patients and their families

Source link Testing for Alzheimer’s disease provides much-needed answers for patients and their families